Retatrutide is a next-generation triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. This VLS pre-filled pen offers precise, convenient administration for metabolic and weight management research.
Quanta Pharma Retatrutide 30mg is a triple agonist peptide that activates GLP-1, GIP, and glucagon receptors. It enhances insulin secretion, increases energy expenditure, and reduces appetite, resulting in significant improvements in weight loss and metabolic regulation.
New! Now in a 10ml Vial! Quanta Pharma Retatrutide 50mg is a triple agonist that activates the GLP-1, GIP, and glucagon receptors. It enhances insulin secretion, increases energy expenditure, and reduces appetite, resulting in significant improvements in weight loss and metabolic regulation. Lab verified 99.84% purity.
SerenQ Retatrutide is the first triple agonist peptide (GLP-1 + GIP + glucagon) supplied in a sealed, pre-filled injection pen. No reconstitution, no bacteriostatic water, no drawing up from vials. Dial the units, read them off the window, dispense.
